Cutler Group LP Supernus Pharmaceuticals, Inc. Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$26.37 - $34.22 $131,850 - $171,100	-5,000 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$23.54 - $31.39 $117,700 - $156,950	5,000 New	5,000 $133,000
Q4 2020 Jan 21, 2021	SELL	$17.7 - $25.81 $8,850 - $12,905	-500 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$32.77 - $41.99 $72,094 - $92,378	-2,200 Reduced 81.48%	500 $17,000
Q4 2018 Feb 05, 2019	BUY	$30.84 - $49.51 $82,897 - $133,082	2,688 Added 22400.0%	2,700 $89,000
Q4 2017 Jan 17, 2018	SELL	$36.4 - $42.6 $233,870 - $273,705	-6,425 Reduced 99.81%	12 $0
Q3 2017 Oct 17, 2017	BUY	$36.75 - $49.65 $236,559 - $319,597	6,437	6,437 $257,000

284

60.5M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.